Diab A, Ascierto PA, Maio M, Abdel-Wahab R, et al. Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol 2025 Jun 25:JCO2501412. doi: 10.1200/JCO-25-01412.
PMID: 40561410